Jefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE